

# Antoine Gosselin, M.A. Economics

2448 Park Row West, Montréal, H4B 2G4  
Office: (514) 504-5310 • Email: [antoine.gosselin@gmail.com](mailto:antoine.gosselin@gmail.com)

---

## PROFESSIONAL EXPERIENCE

2008 – President, Antoine Gosselin consultant inc.  
2007 – 2008 Senior Economist, Groupe d'analyse Itée  
2001 – 2006 Economist, Groupe d'analyse Itée  
2000 – 2001 Research assistant, Chaire Hydro-Québec, Laval University  
1998 Summer Intern, Ministère de l'Environnement du Québec, Economic Analysis Service

## EDUCATION

1998-2003 Master degree in Economics, Laval University  
1998-1999 Bachelor program in biochemistry (first year), Laval University  
1996-1997 Exchange program, Université des Sciences Sociales de Toulouse  
1994-1997 Bachelor degree in Economics (concentration in mathematics), Laval University

## RECENT CASEWORK

### *REGULATION*

On behalf of a consumer advocacy organization, I have been analyzing annual rate cases and various other requests submitted by regulated energy distribution companies before the Régie de l'énergie du Québec on an ongoing basis over the last three years.

I supported Professor Marc Van Audenrode in the preparation of his expert report on the retail gas market competitive landscape presented before Manitoba's Public Utilities Board.

### *FINANCE*

In the context of the international Basel II Accord on risk management in financial institutions, I assessed the credit risk of a large Canadian financial institution. This project involved the evaluation of the internal correlation in multiple classes of financial assets to determine the capital reserve requirements of the institution with respect to the retail credit portfolio.

### *HEALTH ECONOMICS*

My health care experience includes multiple health care related studies including pharmaco-economy, clinical trials, cost-effectiveness, and public health. In particular, I worked on anemia, COPD, and diabetes. I also evaluated the cost of smoking and the cost-effectiveness of smoking cessation therapies and have been involved in the evaluation of the impact of technology on health care costs in the United States. More recently, I studied the impact of compliance to gastroesophageal reflux disease medications on health care outcomes and costs.

## **SELECTED CASEWORK**

### *FLORIDA STATE BOARD OF ADMINISTRATION V. ALLIANCE CAPITAL MANAGEMENT*

*Circuit Court of Leon County, State of Florida*

The Florida State Board of Administration (FSBA) sued Alliance for buying Enron shares and for not following an agreed-upon investment strategy. In support of academic expert Michael Koehn, I built in collaboration with two other colleagues a mathematical model that simulated portfolio returns and generated thousands of return paths accounting for return correlation under various scenarios. The results showed that the return realized by the shareholders was within the bound of what they could have expected from any other portfolio.

### *ASSESSMENT OF DAMAGES TO SHAREHOLDERS ARISING FROM MARKET TIMING ACTIVITIES IN LARGE US MUTUAL FUNDS*

In this litigation case, I was part of a team responsible for measuring damages due to market timing and late trading activities. The work in support of academic expert Marshall E. Blum included the analysis of dilution effects with models that identify these transactions under alternative definitions of market timing, and “but-for” prices under alternative approaches to estimating a fair-value net asset value.

### *KELLOGG COMPANY V. BASF AG, ET AL.*

*United States District Court, District of Columbia*

In this litigation case brought by direct and indirect purchasers of vitamin products, I was part of a team of economists that worked in support to the academic expert Robert S. Pindyck. In the direct purchaser litigations, we developed pricing models to compute “but-for” prices for bulk vitamin products. In the indirect purchaser litigations, we evaluated class certification and calculated damages to plaintiffs. We applied advanced econometric models to transactional and aggregate data to assess pass-through along complex supply chains.

### *NORTHLAND CRANBERRIES V. OCEAN SPRAY*

*United States District Court, District of Massachusetts*

I worked in support of Professor Robert Pindyck in an analysis related to allegations of monopolization and unfair competition pertaining to sales of cranberries, concentrate, and retail juice products. I estimated market elasticities through the implementation of advanced demand models.

### *ORGANON V. MYLAN PHARMACEUTICALS, ET AL*

*United States District Court, District of New Jersey*

In this off-label marketing pharmaceutical litigation I collaborated with an epidemiologist to develop a mathematical algorithm that identified switches between alternative antidepressant drugs in individual patients.

### *ORTHO BIOTECH PRODUCTS, L.P. V. AMGEN INC. AND AMGEN USA INC.*

*United States District Court, District of New Jersey*

In this cost-effectiveness analysis, I coordinated multiple pieces of work in support of Professor Pierre Crémieux in the preparation of his expert report on the relative cost of two leading erythropoietic agents.

## PUBLICATIONS AND PRESENTATIONS

### *HEALTH ECONOMICS*

Duh MS, **Gosselin A**, Luo R, Lohoues H, Lewis B, Crawley J. Impact of Compliance With PPIs on NSAID Treatment in Patients With GERD. *Am J Manag Care*. Forthcoming.

**Gosselin A**, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. *Value in health*. 2009 Jan;12(1): 34-39.

Andermann F, Duh MS, **Gosselin A**, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. *Epilepsia*. 2007 Mar;48(3):464-9.

Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, **Gosselin A**, Tak Piech C. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. *Clin Ther*. 2006 Sep;28(9):1443-50.

**Gosselin A**, Pashos CL, Harley C, Mark TL, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies. *Clin Ther*. 2006 Oct;28(10):1701-8.

Lefebvre P, **Gosselin A**, McKenzie RS, Mody SH, Piech CT, Duh MS. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. *Curr Med Res Opin*. 2006 Sep;22(9):1623-31.

Duh MS, Mody SH, McKenzie RS, Lefebvre P, **Gosselin A**, Bookhart BK, Piech CT. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. *Drugs Aging*. 2006;23(12):969-76.

### *OTHERS*

Bernard JT, **Gosselin A**. Changement de l'efficacité énergétique pour fins de chauffage dans le secteur résidentiel au Québec, 1989-1998. *Energy Studies Review* 2003;11(2) :152-70.

**Gosselin A**. Le traitement des élus municipaux : analyse et facteurs d'influence. Presented at the Annual congress of the Fédération Québécoise des Municipalités, fall 2004.